drugset / Trial / NCT00681889

Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

NCT00681889

Phase 1 Completed 9 enrolled Reza Dana, MD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Timeline

Start
2008-04
Primary completion
2009-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody Topical